In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 39496174.
- Also identified by DOI 10.7326/ANNALS-24-02849-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Apperloo EM, Neuen BL, Fletcher RA, et al. <b>Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.</b> Lancet Diabetes Endocrinol. 2024;12:545-557. 38991584.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Glucagon-Like Peptide-1 Receptor Agonists